A523 nated: rivaroxaban and dabigatran 150mg. The efficiency frontier was constructed by connecting the remaining strategies: warfarin and apixaban. Apixaban resulted in an incremental additional cost of 2,870€ and an incremental QALY of 0.189, corresponding to an ICER of 15,157€ /QALY versus warfarin. The PSA indicated that the probabilities for apixaban being cost-effective versus warfarin were respectively 80% and 90% at the informal willing-to-pay thresholds of 30,000€ and 50,000€. Sensitivity analysis identified stroke risk with apixaban and intracranial hemorrhage risk with warfarin as the variables most influencing the results. ConClusions: Apixaban may be the most economically efficient alternative to warfarin in NVAF patients eligible for stroke prevention in France. All other strategies are dominated. However, uncertainty surrounding these results should be investigated through real life data.
A439were updated to € 2013. Results: The primary analysis compared dapagliflozin with sulfonylureas resulting in 0.525 additional QALYs and € 1,835 additional cost (cost-effectiveness ratio of € 3,496/QALY). The higher drug cost of dapagliflozin was partially offset by lower costs of complications, hypoglycemia and the cost associated with weight gain. In the secondary analyses, dapagliflozin was a cost-effective option compared with thiazolidinediones and DPP4, resulting in a cost per QALY gained of € 20,183 and € 487, respectively. The univariate and probabilistic sensitivity analyses confirmed the robustness of the results. ConClusions: Dapagliflozin in combination with metformin proved to be a cost-effective alternative compared to sulfonylureas, thiazolidinediones and DPP4 inhibitors in the treatment of T2DM.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.